In March, the European Patent Office's Enlarged Board of Appeal issued its G 2/21 decision on plausibility, providing guidance on the circumstances under which post-published evidence may be used when determining inventive step. Then, in May, the U.S. Supreme Court issued its decision on enablement in Amgen v. Sanofi, holding that patents that cover an entire class of processes, machines, manufactures, or compositions of matter using broad, functional language must enable a person skilled in the art to make and use the entire See more +

In March, the European Patent Office's Enlarged Board of Appeal issued its G 2/21 decision on plausibility, providing guidance on the circumstances under which post-published evidence may be used when determining inventive step. Then, in May, the U.S. Supreme Court issued its decision on enablement in Amgen v. Sanofi, holding that patents that cover an entire class of processes, machines, manufactures, or compositions of matter using broad, functional language must enable a person skilled in the art to make and use the entire class.

What insights can patent owners and prosecutors glean from these recent developments? On July 19, join Principals Moritz Ammelburg and Peter Fasse for a discussion of current patent prosecution issues in the U.S. and Europe. The webinar will cover:

- The Supreme Court's decision in Amgen v. Sanofi

- The EPO Enlarged Board of Appeal's plausibility case

- Lessons these cases present for drafting and claiming See less -